In vivo evaluation of 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2- nitrophenyl)-O-β-D-glucopyronuronate: A positron emission tomographic tracer for imaging β-Glucuronidase activity in a tumor/inflammation rodent model

Molecular Imaging

Volumn 11, Issue 1, 2012, Pages 77-87

  Antunes, Inês F ^a   Haisma, Hidde J ^a   Elsinga, Philip H ^a   Van Waarde, Aren ^a   Willemsen, Antoon T M ^a   Dierckx, Rudi A ^a   De Vries, Erik F J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIODISTRIBUTIONS; DEGENERATIVE PROCESS; DIFFERENT SIZES; DISTRIBUTION VOLUME; EX-VIVO; GLUCURONIDASE; IN-CONTROL; IN-VIVO; MICROPET; PET IMAGING; PET TRACER; PHARMACOKINETIC MODELING; POSITRON EMISSION; PRODRUGS; RODENT MODELS; SOLID TUMORS; TOMOGRAPHIC; WISTAR RAT;

DISEASES; MUSCLE; PATHOLOGY; POSITRONS;

TUMORS;

BETA GLUCURONIDASE;

ANIMAL; ARTICLE; ENZYMOLOGY; GLIOMA; METABOLISM; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RAT; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; CELL LINE, TUMOR; GLIOMA; GLUCURONIDASE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, WISTAR;

EID: 84857268717     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00029     Document Type: Article

References (19)

1. de Graaf M, Pinedo HM, Oosterhoff D, et al. Pronounced antitumor efficacy by extracellular activation of a doxorubicinglucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein. Hum Gene Ther 2004;15:229-38, doi: 10.1089/104303404322886084. (Pubitemid 38365912)
2. George J. Elevated serum beta-glucuronidase reflects hepatic lysosomal fragility following toxic liver injury in rats. Biochem Cell Biol 2008;86:235-43, doi: 10.1139/O08-038. (Pubitemid 351810523)
3. Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res 1993;60:269-91, doi: 10.1016/S0065-230X(08) 60828-3.
4. Chen X, Wu B, Wang PG. Glucuronides in anti-cancer therapy. Curr Med Chem Anticancer Agents 2003;3:139-50, doi: 10.2174/1568011033353470. (Pubitemid 36221734)
5. de Graaf M, Boven E, Scheeren HW, et al. Beta-glucuronidasemediated drug release. Curr Pharm Des 2002;8:1391-403, doi: 10.2174/1381612023394485. (Pubitemid 34591354)
6. de Groot FM, Damen EW, Scheeren HW. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem 2001;8:1093-122. (Pubitemid 32633661)
7. Bosslet K, Straub R, Blumrich M, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195-201. (Pubitemid 28183208)
8. Houba PH, Boven E, van der Meulen-Muileman IH, et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br J Cancer 2001;84:550-7, doi: 10.1054/bjoc. 2000.1640. (Pubitemid 32215885)
9. Prijovich ZM, Chen BM, Leu YL, et al. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br J Cancer 2002;86:1634-8, doi: 10.1038/sj. bjc.6600317. (Pubitemid 34628119)
10. Sperker B, Murdter TE, Schick M, et al. Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther 1997;281:914-20. (Pubitemid 27203827)
11. Sperker B, Werner U, Murdter TE, et al. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn Schmiedebergs Arch Pharmacol 2000;362:110-5, doi: 10.1007/s002100000260. (Pubitemid 30640038)
12. Antunes IF, Haisma HJ, de Vries EF. Tumor-specific activation of prodrugs: is there a role for nuclear medicine? Nucl Med Commun 2008;29:845-6, doi: 10.1097/MNM.0b013e3283094efc.
13. Brady F, Luthra SK, Brown GD, et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des 2001;7:1863-92, doi: 10.2174/1381612013396907. (Pubitemid 33138603)
14. Tzou SC, Roffler S, Chuang KH, et al. Micro-PET imaging of betaglucuronidase activity by the hydrophobic conversion of a glucuronide probe. Radiology 2009;252:754-62, doi: 10.1148/radiol.2523082055.
15. Antunes IF, Haisma HJ, Elsinga PH, et al. Synthesis and evaluation of [(18)F]-FEAnGA as a PET tracer for beta-glucuronidase activity. Bioconjug Chem 2010;21:911-20, doi: 10.1021/bc9004602.
16. van Waarde A, Jager PL, Ishiwata K, et al. Comparison of sigmaligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006;47:150-4. (Pubitemid 46768524)
17. Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005;32:294-301, doi: 10.1007/s00259-004-1566-1. (Pubitemid 40562120)
18. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45, doi: 10.2967/jnumed.106.035774. (Pubitemid 46909922)
19. Akaike H. [Data analysis by statistical models]. No To Hattatsu 1992;24:127-33.